[ad_1]
HealthDay Information – In accordance with a analysis letter revealed on-line on Aug. 11, the seropositivity fee in most cancers sufferers stays excessive even 4 months after the second dose of the COVID-19 vaccine JAMA oncology.
Noa Eliakim-Raz, MD, of Rabin Medical Middle in Petah Tikva, Israel, and colleagues studied the anti-spike (anti-S) immunoglobulin (Ig) G antibody response to the messenger RNA vaccine (BioNTech-Pfizer ) in 95 most cancers sufferers versus 66 controls about 4 months after the second vaccination dose.
The researchers discovered {that a} median of 123 days after the second vaccination, 87 p.c of the sufferers and 100 p.c of the controls have been seropositive for anti-S-IgG antibodies. In most cancers sufferers, the imply titer values have been considerably decrease than within the management group (417 versus 1,220 arbitrary models per milliliter). The median IgG titers assorted by 3.6-fold relying on the tumor sort and eight.8-fold relying on the kind of most cancers therapy, the bottom titers being noticed with immunotherapy plus chemotherapy and organic remedy.
Proceed studying
“Lengthy-term mobile reminiscence might query the necessity for a 3rd BNT162b2 booster dose,” the authors write.
One creator introduced monetary ties to the pharmaceutical business.
Abstract / full textual content (subscription or fee could also be required)
[ad_2]
Discussion about this post